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Abstract: Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that have been shown to pos-
sess therapeutic properties since they are able to prevent the development of some diseases, as shown mostly on animal 
models for cancer, infections and gastrointestinal disorders such as intestinal inflammation. LAB have been shown to 
regulate mucosal immune responses by modulating the production and liberation of regulatory agents such as cytokines by 
the host. Some of these cytokines, such as the anti-inflammatory interleukin-10 (IL-10), modulate the inflammatory im-
mune response, thus immunomodulation is a mechanism by which LAB can prevent certain inflammatory bowel diseases 
(IBD). Since oxidative stress participates in the inflammatory processes and in the appearance of damages in pathologies 
of the gastrointestinal tract of humans such as IBD, LAB could also prevent inflammation by eliminating reactive oxygen 
species (ROS) through the activity of antioxidant enzymes. In order to obtain novel strains or enhance beneficial effects of 
LAB, genetic engineering has been used to produce either antioxidant enzymes (such as catalases and superoxide dismu-
tases) or anti-inflammatory cytokines (such as IL-10) producing LAB. These novel strains have successfully been used to 
prevent inflammatory bowel diseases in animal models and could be evaluated in human clinical trials. Here, we present 
an overview of the current knowledge of the mechanisms by which LAB can be used to prevent undesired intestinal in-
flammatory responses and could be used as a therapeutic tool for IBD. 
Keywords: Anti-inflammatory, antioxidant, catalase, immune regulation, interleukin-10, lactic acid bacteria, superoxide 
dismutase. 
INTRODUCTION 
 Despite many years of study, the exact etiology and 
pathogenesis of inflammatory bowel diseases (IBD) remain 
unclear but great advances have been made using experimen-
tal animal models and have provided insights into the com-
plex, multi-factorial processes and mechanisms that can re-
sult in chronic intestinal inflammation. 
 Lactic acid bacteria (LAB) represent a heterogeneous 
group of microorganisms that are naturally present in many 
foods and have long been consumed by humans without any 
obvious adverse effects [1]. Some selected strains, with well-
defined characteristics, are frequently added as probiotics in 
order to confer specific benefits to consumers. Many studies 
have shown that LAB possess therapeutic properties since 
they can modulate the host immune system, act as a barrier 
or produce antimicrobial substances against certain patho-
gens, reduce cholesterol levels, decrease the frequency and 
duration of diarrhoea that are associated with antibiotic us-
age or rotavirus infections, and can prevent some diseases 
such as cancer, infections, and gastrointestinal disorders such 
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as intestinal inflammation. Most of these investigations have 
been performed using animal models; however, clinical stud-
ies are now confirming that probiotic LAB are also effective 
in preventing and treating diseases in humans. Since probiot-
ics are generally administered via the oral route, most of 
their beneficial effects take place at the intestinal level where 
many studies on the mechanisms involved in the prevention 
and treatment of intestinal disorders have been focused [2]. 
There is now mounting evidence suggesting that LAB have 
anti-inflammatory properties that prevent and alleviate cer-
tain intestinal disorders. The present review will give an 
overview of the current knowledge of the mechanisms of 
these anti-inflammatory properties. 
IMMUNE SYSTEM AND LAB 
 The gut microbiota plays an important role in the control 
of certain human diseases. Moreover, an increasing number 
of clinical and experimental studies have demonstrated that 
the intestinal microbiota may modulate the inflammatory 
responses in allergic and inflammatory bowel diseases (IBD) 
[3]. Probiotic bacteria can counteract inflammatory processes 
by stabilizing the gut microbial environment and the intes-
tine’s permeability barrier, and by enhancing the degradation 
of enteral antigens and altering their immunogenicity (re-
viewed in [4]). Many beneficial effects of probiotics are re-
lated to their immunomodulatory effects: immune-enhancing 
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as well as anti-inflammatory activities [5]. A healthy homeo-
stasis in the gut may thus be achieved by optimizing the bal-
ance of pro- and anti-inflammatory cytokines and other me-
diators. Accumulating evidence indicates that the establish-
ment and maintenance of intestinal and systemic tolerance 
are mainly dependent on suppressive cytokines, such as in-
terleukin (IL)-10 and transforming growth factor- (TGF-), 
produced by regulatory T cells and T helper cells which are 
characteristic of the intestinal immune system [6-8]. The 
tolerogenic effects of the gut microbiota may partially be 
mediated by generation of these regulatory T cells. Indeed, 
certain LAB strains, normal inhabitants of the gut microbi-
ota, have been shown to contribute to T helper cell popula-
tions which promote oral tolerance induction, preventing 
hypersensitivity and local inflammation [7, 9]. It was also 
shown that Lactobacillus (L.) rhamnosus GG conditioned 
media decreased tumor necrosis factor (TNF-) production 
by macrophages in vitro by a contact independent mecha-
nism [10]. Other studies have shown the specificity of bacte-
rial strains in inducing anti- or proinflammatory cytokines. 
Indeed, some LAB, or their products, orally administered in 
mice (L. reuteri or L. brevis), had a stimulatory effect on the 
secretion of proinflammatory cytokines such as IL-1 and 
TNF- [11]. The immunomodulatory properties of LAB, 
through the repression of proinflammatory cytokines, could 
be one of the mechanisms by which these probiotic microor-
ganisms are able to prevent and treat certain inflammatory 
diseases in the gastrointestinal tract. However, it is important 
to note that the extrapolation from in vitro to in vivo results 
is not easy. In this sense, Mileti et al. [12] reported a work 
where three LABs were compared and showed that these 
probiotics inhibited direct or indirect DC activation by in-
flammatory bacteria, however some of these not only failed 
to protect against DSS-induced colitis in mice, they actually 
amplified the disease progression. Proper animal trials fol-
lowed by human clinical trials are thus essential in confirm-
ing the probiotic anti-inflammatory effect of probiotic bacte-
ria. 
PROBIOTICS AS TREATMENTS FOR INFLAMMA-
TORY BOWEL DISEASE  
 The effectiveness of probiotics in the alleviation of diges-
tive diseases are first tested in animal models to elucidate 
their possible mechanisms of action. In this sense, several 
animal models have been used to test different probiotic bac-
teria and fermented products. There are also evidences that 
suggest that non-living probiotic bacteria can prevent the 
development of certain forms of intestinal inflammation. In 
this sense, Zakostelska et al. [13] reported that lysates of 
probiotic L. casei DN-114 001 reduced the severity of acute 
dextran sulfate sodium (DSS) colitis in BALB/c mice. This 
effect was mediated by beneficial changes on the intestinal 
microbiota and immune system (increases of IL-10 by Treg 
cells and decreases of pro-inflammatory cytokines). The 
anti-inflammatory effect of L. salivarius Ls33 and its pepti-
doglycan (PGN) was studied using the 2,4,6-trinitrobenzene 
sulfonic acid (TNBS) colitis model. This activity was IL-10-
dependent, favoring the development of regulatory dendritic 
cells and CD4(+)Foxp3(+) regulatory T cells [14]. It is im-
portant to note that this protective capacity was not obtained 
with PGN purified from a non-anti-inflammatory strain. The 
structural analysis of PGNs from L. salivarius Ls33 showed 
the presence of an additional muropeptide, M-tri-Lys which 
also protected mice from colitis.  
 Another bacterial compound that could be implicated in 
the anti-inflammatory effect of LAB is the lipoteichoic acid 
(LTA), the major cell wall compound of lactobacilli. It is 
known that LTA molecules of certain bacteria can induce 
pro-inflammatory signaling in macrophages by interaction 
with TLR-2 [15], but it was also reported that changing the 
structure of LTA by removing D-alanine residues might af-
fect its interactions with other surface molecules and there-
fore cause pleiotropic effects that can impact indirectly on 
the anti-inflammatory capacity of the lactobacilli [16]. This 
experiment was carried out with L. rhamnosus GG (LGG), 
comparing the wild-type and dltD mutant strains. Mice 
treated with the dltD mutant showed an improvement of 
some colitic parameters compared to LGG wild-type-treated 
mice, with a significant down-regulation of Toll-like recep-
tor-2 expression and decrease of pro-inflammatory cytoki-
nes. These results with the LGG dltD mutant show the poten-
tial of modifying some structures of the probiotic cell surface 
to have an improvement in the treatment of IBD. Other 
modified LABs with potential in treatment of IBD will be 
described latter in this article.  
 Recently, several randomized controlled trials have now 
confirmed the beneficial effects of probiotics in humans with 
IBD including Crohn’s disease, irritable bowel syndrome, 
pouchitis and ulcerative colitis. Some examples of these 
clinical trials with the most relevant beneficial effects of 
probiotics supplementation are shown in Table 1. 
 Hedin et al., [35] reported a case-control study about the 
use of probiotics and prebiotics in patients with IBD. They 
described that a high percentage of IBD patients used probi-
otics to manage their health compared to controls (without 
IBD). They noted that many patients rely on nonclinical 
sources of information and considered that not all probiotics 
can be useful for all the IBD, suggesting that healthcare pro-
viders should inquire about probiotic use in their patients and 
give evidence-based advice.  
 The results of the trials listed in Table 1 confirm the ef-
fectiveness of certain probiotic strains in the treatment and 
prevention of IBD. However, only a few of these reports 
describe mechanisms of these anti-inflammatory effects. 
 Gionchetti et al. [27] performed a double-blind random-
ized controlled trial (RCT) comparing the effects of VSL#3 
probiotic mixture and a placebo to prevent the recurrence of 
chronic relapsing pouchitis, an IBD occurring after surgical 
resection of the colon. A relapse occurred in 15% of those in 
probiotics group versus 100% in the placebo group. This 
result was confirmed in a second multi-center double-blind 
RCT where the relapse at one year was 10% in the probiot-
ics-treated patients versus 94% in the placebo-treated pa-
tients [26]. A link between VSL#3 anti-inflammatory capaci-
ties and Toll-like receptors (TLR) was established by 
Rachmilewitz et al. who showed that the probiotic treatment 
prevents inflammation via the recognition of bacterial DNA 
by TLR9 using a mouse colitis model [36]. Interestingly, the 
probiotic treatment increased the tissue levels of IL-10 in
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Table 1. Examples of Human Clinical Trials (Randomized Controlled Trials) that have Demonstrated that Probiotics Improve In-
flammatory Bowel Diseases Including Crohn’s Disease (CD), Irritable Bowel Syndrome (IBS), Pouchitis (PCH) and Ul-
cerative Colitis (UC)  
Disease n= Results Probiotic * Ref. 
CD 32 
Relapse in 6% of patients supplemented with probiotic strain vs. 38% with conven-
tional treatment only. 
S. boulardii [17] 
CD 6 
Median pediatric CD activity index scores at 4 weeks were 73% lower than baseline 
and intestinal permeability improved in an almost parallel fashion. 
L. rhamnosus GG [18] 
CD 21 
The number of specific  IgA secreting cells in the class to -lactoglobulin increased 
significantly from 0.2 to 1.4 / 106 cells and to casein from 0.3 to 1.0 / 106 cells. 
L. rhamnosus  GG [19] 
IBS 77 
Alleviation of IBS symptoms and normalization of the ratio of an anti-inflammatory to a 
proinflammatory cytokine in patients receiving probiotic strain vs. placebo group. 
B. infantis 35624 [20] 
IBS 48 
Relapse in 20% of patients in probiotic group vs 93% in the placebo group. The pro-
biotic impeded the activation of NF-B, decreased the expressions of TNF- and  
IL-1 and increased the expression of IL-10. 
BIFICO (3 bifidobacteria species) [21] 
IBS 103 
The total symptom score (abdominal pain + distension + flatulence + borborygmi) 
was reduced 42% in probiotic group compared with 6% in the placebo group.  
L. rhamnosus GG, L. rhamnosus 
Lc705, P. freudenreichii ssp 
shermanii JS, B. breve Bb99 
[22] 
IBS 25 
The probiotic+prebiotic treatment showed short-term and long-term reductions in IBS 
symptoms.  
Prescript-Assist (probiotic-prebiotic 
complex containing 29 soil-based, 
pH-resistant micro-flora) 
[23] 
IBS 25 
The probiotic+prebiotic treatment was associated with significant reductions in 3 sub-
syndromic factors of IBS: general ill feelings/nausea, indigestion/flatulence, and colitis. 
Prescript-Assist  [24] 
IBS 67 The probiotic improved the  quality of life in patient with IBS.  S. boulardii [25] 
PCH 36 
The probiotic mixture was effective in maintaining antibiotic introduced remission 
for at least a year in patients with recurrent or refractory pouchitis (85%) vs 6% in the 
placebo group. 
VSL#3 (probiotic preparation 
containing 3 B., 4 L. and  
1 St. strains) 
[26] 
PCH 40 
10% of patients treated with probiotics had an episode of acute pouchitis compared 
with 40% treated with placebo. Treatment with probiotic improved Inflammatory 
Bowel Disease Questionnaire score vs placebo.  
VSL#3 [27] 
PCH 31 
The probiotic mixture administration in patients with  ileal pouch anal anastomosis 
modulated the disease activity and increased the number of mucosal regulatory T cells. 
VSL#3 [28] 
UC 18 
Sigmoidoscopy scores were reduced in probiotic group compared with placebo.  
TNF- and IL-1 were reduced after treatment with probiotic.  
Symbiotic therapy  
(B. longum and Synergy1) 
[29] 
UC 327 
The probiotic treatment was just as effective as conventional treatment (mesalazine) 
in maintaining remission.  
E. coli Nissle 1917 [30] 
UC 90 
Probiotic supplementation improved remission compared to conventional treatment 
(balsalazide) alone.  
VSL#3 [31] 
UC 21 Probiotic preparation maintains remission (75%).  VSL#3 [32] 
UC 120 
62% improvement of symptoms and 0% relapse of intestinal disease while patients 
were on probiotics. 
VSL#3 [33] 
UC 29 
Pediatric, randomized, placebo-controlled trial that suggests the efficacy and safety of 
this probiotic mixture in active UC and in maintenance of remission. 
VSL#3 [34] 
*microbial abbreviations: S. (Saccharomyces), B. (Bifidobacterium). L. (Lactobacillus), St. (Streptococcus), P. (Propionibacterium), E. (Escherichia). 
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these patients [37]. IL-10 is an anti-inflammatory cytokine 
that is involved in the suppression of the release of pro-
inflammatory cytokines such as TNF-, interferon- (IFN-) 
and IL-1 [38]. Recently, the first pediatric, randomized, 
placebo-controlled trial using this probiotic mixture in pa-
tients with ulcerative colitis was published. Remission was 
achieved in 13 patients out of 29, treated with VSL#3 and 
IBD therapy and in 4 patients treated with placebo and IBD 
therapy (P<0.001). Three of the 14 patients treated with 
VSL#3 and IBD therapy and 11 of 15 patients treated with 
placebo and IBD therapy relapsed within 1 year of follow-
up, the endoscopic and histological scores being significantly 
lower in the VSL#3 group than in the placebo group 
(P<0.05) [34]. 
 A pilot study has suggested that L. rhamnosus GG may 
improve gut barrier function and clinical status in children 
suffering from mildly to moderately active, stable Crohn's 
disease (CD) [18]. In CD, abnormal activation of mucosal T 
lymphocytes against enteric bacteria is the key event trigger-
ing intestinal inflammation. Carol et al. [39] demonstrated 
that a probiotic strain of L. casei reduces the number of acti-
vated T lymphocytes in the lamina propria of CD mucosa, 
diminishing the release of IL-6 and TNF- and lowering the 
expression of the anti-apoptotic protein Bcl-2. In addition, 
co-culture with L. casei significantly reduced the number of 
T cells displaying the IL-2 receptor in the lamina propria.  
 The results of these trials show that some probiotic 
strains can successfully modify the mucosal immune re-
sponse to modulate the levels of specific activation mole-
cules such as cytokines. By increasing IL-10 levels and, in 
consequence, decreasing inflammatory cytokines such as 
TNF- and IFN-, some LAB can prevent the appearance of 
local inflammatory diseases and can successfully be used as 
an adjunct therapy with conventional treatments. 
 The crucial role of IL-10 in the development of IBD has 
been demonstrated by experiments in IL-10–deficient mice. 
These animals develop a chronic bowel disease resembling 
CD in humans, which is in part caused by a loss of suppres-
sion of the mucosal immune response toward the normal 
intestinal microbiota [40]. Unfortunately, systemic IL-10 
treatment of CD patients is not very effective in inducing 
clinical remission and is associated with considerable side 
effects, which are partly due to the fact that systemic IL-10 
induces the pro-inflammatory cytokine IFN- [41]. However, 
studies in experimental models suggest that topical treatment 
with IL-10 is effective in preventing certain inflammatory 
diseases. LAB are potent candidates as delivery vehicles of 
beneficial compounds because of their GRAS status (gener-
ally recognized as safe) and expression of heterologous pro-
teins and antigens, as well as various delivery systems are 
now available for these probiotic microorganisms [42]. In-
tragastric administration of a recombinant Lactococcus (Lc.) 
lactis strain secreting murine IL-10 prevented the onset of 
colitis in IL-10 knockout mice and caused a 50% reduction 
of the inflammation in dextran sulfate sodium-induced 
chronic colitis in these animals [43]. Braat et al. [44] have 
recently published the first report of a human clinical phase I 
trial with a genetically engineered therapeutic bacterium that 
secretes mature human IL-10. Ten CD patients were in-
cluded in this phase I trial and received capsules, twice daily 
during 7 days, with the transgenic bacteria expressing IL-10. 
The lack of a control group, as is intrinsic to a phase I study, 
does not allow conclusions regarding the clinical efficacy of 
this specific bacterium, however, the lack of undesired side-
effects shows that the use of genetically modified bacteria 
for mucosal delivery of proteins is a feasible strategy in hu-
man beings. This novel strategy avoids systemic side effects 
and can be biologically contained as described in this study; 
therefore, genetically modified LAB could be suitable for 
use as treatments for chronic intestinal diseases by delivering 
beneficial compounds (such as IL-10) to specific sites in the 
gastrointestinal tract where they are required. 
PROBIOTICS AND INFLAMMATION BEYOND THE 
INTESTINAL TRACT 
 Probiotic microorganisms can also be efficient in the 
treatment of other inflammatory diseases that occur at other 
sites besides the gastrointestinal tract, such as in the case of 
allergic inflammation [45]. It has been reported that infants 
who were allergic to cow’s milk and treated with hydrolyzed 
milk formula supplemented with L. rhamnosus GG, had a 
better clinical score and less TNF- in their faeces than in-
fants treated with the hydrolysed formula alone [46], show-
ing a positive effect of this bacteria on food allergy induced 
inflammatory processes. 
 Perdigon et al. [5] have shown that fermented products 
and probiotics can activate immune cells at sites distant to 
the intestinal mucosa, such as bronchus and breast tissues. A 
fermented milk containing L. helveticus R389 was able to 
regulate the immune response in mammary glands in pres-
ence of a local inflammatory pathology (breast tumor) in 
mice [47]. The administration of milk fermented by this 
LAB strain delayed or stopped breast tumor development 
due to a modulation in the immune response which was 
manifested by an increase of the anti-inflammatory cytokine 
IL-10 [48]. A recent review by DeNardo and Coussens [49] 
showed that breast tumor promotion and rejection can be 
mediated by cytokines involved in chronic and acute in-
flammatory processes such as IL-10 which can be modulated 
by LAB. 
REACTIVE OXYGEN SPECIES  
 Since oxidative stress and epithelial damages appear 
linked in pathologies of the gastrointestinal tract of humans 
such as IBD, another mechanism by which LAB could pre-
vent inflammation is through the use of antioxidant enzymes 
that can degrade reactive oxygen species (ROS) or impair 
their formation. 
 ROS are small molecules (such as superoxide ions, free 
radicals and peroxides) that are formed as byproducts of the 
normal metabolism of oxygen. The biological sources of 
ROS are numerous: they can be generated in aerobiosis by 
flavoproteins [50] and by phagocytes during inflammatory 
reactions [51]. ROS, in low quantities, participate in cell 
signaling and regulatory pathways. When they are produced 
in large amounts, as is the case during inflammatory proc-
esses, they act to eliminate infectious agents by causing sig-
nificant damages to cell structures and macromolecular con-
stituents such as DNA, RNA, proteins and lipids [52]. Toxic-
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ity occurs when the concentration of ROS exceeds the capac-
ity of cell defence systems [53]. Large amounts of H2O2 are 
produced and excreted by human tumor cells [54] and might 
participate in tumor invasion and proliferation. In IBD pa-
tients, oxidative stress occurs as a result of recurrent and 
abnormal inflammation. A correlation between the increase 
in ROS production and disease activity in inflamed biopsies 
of IBD patients has been established in various studies [55-
58]. Thus, oxidative stress plays an important role in pa-
thologies of the gastrointestinal tract of humans such as IBD 
and certain types of cancers [59, 60].  
 The normal intestinal mucosa is equipped with a network 
of antioxidant enzymes that neutralize ROS in a two-step 
pathway. First, superoxide dismutases (SODs) convert the 
primary superoxide anion  (O2-) into the more stable metabo-
lite, hydrogen peroxide (H2O2). Second, H2O2 is converted to 
water by catalase (CAT) or glutathione peroxidase (GPO). 
The activities of these enzymes are usually balanced to main-
tain a low and continued steady-state level of ROS. How-
ever, the levels of these enzymes in inflammatory disease 
patients, such as those suffering from IBD, are frequently 
depleted [56, 59], highlighting the potential for increasing 
the local levels of these enzymes to function as a therapeutic. 
Probiotic LAB strains expressing high levels of SOD and 
CAT could increase these enzyme activities in specific loca-
tions of the gastrointestinal tract and could thus contribute to 
prevent oxidative epithelial damages, giving rise to potential 
applications for the treatment of inflammatory diseases or 
post-cancer drug treatments. 
GENETICALLY ENGINEERED LAB-ANTIOXIDANT 
ENZYME AND IL-10 PRODUCTION 
 Catalases are widespread in aerobic (facultative or not) 
bacteria such as Escherichia coli and Bacillus (B.) subtilis 
[61]. Two classes of catalases are distinguished, according to 
their active-site composition: one is heme-dependent and the 
other, also named pseudocatalase, is manganese-dependent. 
Since the majority of LAB are not equipped with enzymes to 
detoxify oxygen-derived compounds, the insertion of genes 
coding for antioxidant enzymes (such as catalases or SOD) 
in probiotic bacteria could improve their anti-inflammatory 
properties beyond the modulation of the local immune-
dependant inflammation response. Catalases of three lacto-
bacilli have been successfully cloned and expressed in het-
erologous bacteria lacking catalase activity [62-65].  
 The food-grade Lc. lactis is a potential vector to be used 
as a live vehicle to deliver heterologous proteins for vaccine 
and pharmaceutical purposes. Since Lc. lactis has no cata-
lase, Rochat et al. [61] introduced the B. subtilis heme cata-
lase KatE gene into this industrially important microorgan-
ism giving rise to a strain capable of producing active cata-
lase that can provide efficient antioxidant activity. A recent 
report has shown that this genetically engineered strain was 
able to prevent tumor appearance in an experimental 
DMH-induced colon cancer model [66]. The catalase pro-
ducing Lc. lactis strain used in this study was able to slightly 
increase catalase activities in the intestines of mice treated 
with dimethylhydrazine (DMH), a colon cancer inducing 
drug. This increased antioxidant activity was sufficient to 
reduce H2O2 levels in the large intestines, a ROS involved in 
cancer promotion and progression, showing that this cata-
lase-producing LAB could be used in novel therapeutic 
strategies for gastrointestinal pathologies. 
 Recently, the heterologous expression of a non-heme 
catalase in bacteria relevant to dairy industries has been re-
ported [65]. A strain of L. casei was constructed to offer the 
advantage that no heme has to be added to the culture me-
dium for catalase activity. Although this strain was able to 
reduce cecal and colonic inflammatory scores, no significant 
differences were observed compared to the use of the native 
non-catalase producing strain in a dextran sulfate sodium 
(DSS)-induced colitis mice model [67]. This is probably due 
to the insufficient production of catalase by this strain in the 
gastrointestinal tract. These authors suggest that in order to 
optimize their antioxidative strategy, evaluation of the ef-
fects of co-administration of L. casei strains producing high 
levels of catalase and SOD from Lc. lactis [68] will be rele-
vant as some previous studies showed the positive impact of 
increased SOD activity in intestinal inflammation models 
[59, 69, 70]. 
 In another study, using a different model of IBD, we 
have shown that a catalase producing strain of L. casei BL23 
significantly decreased the physiological damages caused by 
the TNBS administration [71]. This result was related to the 
antioxidant capacity of the bacterial strain more than an im-
munomodulatory effect. 
 LAB have been used to locally deliver SOD directly to 
the intestines, an important breakthrough since oral ad-
ministration of SOD is greatly limited by its short lifespan 
(5–10min) in the hostile conditions of the gastrointestinal 
tract.  
 To determine whether a bacterial supply of SOD into the 
colon could improve an experimentally induced colitis, Han 
et al. [72] compared the effects of oral treatment with live 
recombinant Lc. lactis or L. plantarum producing different 
amounts of SOD with those of colonic infusion of commer-
cial SOD. Macroscopic damages were reduced by the SOD 
producing strains in rats administered with trinitrobenzene 
sulfonate (TNBS) to induce colitis. Although not all of the 
anti-inflammatory effects could be attributed directly to SOD, 
the results of this study suggest that SOD-producing lactic 
acid bacteria could be used as a novel treatment of IBD. 
 Carroll et al. [73] have recently published a report where 
they investigated the ability of SOD from Streptococcus 
thermophilus to reduce colitis symptoms in IL-10 deficient 
mice using L. gasseri as a delivery vehicle. The L. gasseri 
producing SOD had significant anti-inflammatory activity 
which was associated with a reduction in the infiltration of 
neutrophils and macrophages that significantly reduced the 
severity of colitis in the IL-10-deficient mice.  
 Recent data has shown that SOD producing L. casei 
BL23 was able to significantly attenuate the TNBS-induced 
damages as shown by higher survival rates, decreased animal 
weight loss, lower bacterial translocation to the liver and the 
prevention of damage to the large intestines [71]. This is in 
agreement with previous results that have shown that the 
same SOD-expressing strain of L. casei was able to slightly 
attenuate the colonic histological damage score of a DSS-
induced colitis model [74]. 
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 These results pave the way for the creation of novel ge-
netically modified strains that could produce SOD and cata-
lase concomitantly, giving rise to novel super-antioxidant 
strains that could be used for the treatment and/or prevention 
of inflammatory intestinal diseases caused by oxidative 
stress.  
 A novel regulated expression system with the ability of 
targeting heterologous proteins to the cytoplasm or to the 
extracellular medium has been described for Lc. lactis 
NCDO2118 strain. XIES is a food grade expression system 
that is tightly regulated by a sugar (xylose) that is rarely 
found in conventional foods and acts as inductor. When 
xylose is present in the media, IL-10 is expressed in high 
levels. On the other hand, the presence of glucose inhibits 
IL-10 expression. In this way, IL-10 expression can be up or 
down-regulated [75].  
 This expression system, using Lc. lactis that produce 
IL-10, showed that induction with xylose increased the cyto-
kine levels (>500 pg/ml for the Cyt strain and >1000 pg/ml 
for the Sec strain). It has been demonstrated that Lc. lactis 
producing IL-10 in the cytoplasm showed a higher inmuno-
modulatory potential in a murine lung inflammation model; 
hypothesizing that the recombinant IL-10 produced in the 
cytoplasmic form and stored within the bacteria is probably 
kept under optimum conditions for a longer period of time 
and is slowly released in the tissue together with the bacterial 
host lysis [76].  
 This same Lc. lactis strain using the XIES expression 
system were employment to ferment milks as a new form of 
administration of IL-10 producing Lc. lactis and was effec-
tive in the prevention of IBD in a murine model. Mice that 
received milks fermented by Lc. lactis strains producing 
IL-10 in the cytoplasm (Cyt strain) or secreted to the product 
(Sec strain) showed lower macroscopic and microscopic 
damage scores in their large intestines, decreased IFN- lev-
els in their intestinal fluids and lower microbial translocation 
to liver, compared to mice receiving milk fermented by the 
wild-type strain or those not receiving any treatment [77]. 
Furthermore, in healthy mice, without inflammatory (TNBS) 
stimulus, the number of cytokine positive immune cells and 
cytokine release in the large intestine tissue from the groups 
that received fermented milks compared to the control ani-
mals did not differ significantly, showing that changes in the 
cytokine profile observed in the TNBS model were induced 
by the inflammatory agent and not by the fermented product 
itself. 
 Some proven anti-inflammatory strains, both native and 
genetically modified and divided by their mechanism of ac-
tion are described in Table 2. The beneficial properties of 
these strains could be combined together with others to pro-
duce novel strains exerting a variety of beneficial effects. For 
example, the introduction of antioxidant enzyme genes (SOD 
and CAT) in current probiotic strains that have natural anti-
inflammatory properties, such as the ability to modulate the 
immune-dependent anti-inflammatory processes or the mix-
ture of probiotics with other genetically engineered LAB 
strains that produce anti-inflammatory cytokines could gen-
erate very potent products that could be used in the treatment 
of a variety of inflammatory diseases. These novel products 
with therapeutical purposes could be suitable for specific 
populations suffering from gastrointestinal or other inflam-
matory disorders, or prone to acquiring them.  
 
Table 2. Examples of Bacterial Strains, Native and Genetically Modified (GM), or Probiotic Products with Proven Anti-
inflammatory Properties Classified by their Mechanisms of Action: Immune Dependant Anti-inflammatory Properties 
(Immune) or Antioxidant Enzyme Producers such as Catalase (CAT) or Superoxide Dismutase (SOD) 
Strain * Type Mechanism Proven Effects Ref. 
B. longum Native Immune 
Improvement of clinical appearance of chronic inflammation in 
patients. Decreases in TNF- and IL-1  [29] 
BIFICO (3 bifidobacteria species) Native Immune 
Prevention of flare-ups of chronic ulcerative colitis, inactivation of 
nuclear factor-kB (NF-kB), decreased the expressions of TNF- and 
IL-1 and elevated the expression of IL-10. 
[21] 
L. salivarius ssp. salivarius 
CECT5713 
Native Immune 
Recovery of inflamed tissue in TNBS model of rat colitis, increase in 
TNF- and iNOS (inducible NO synthase) expression. [78] 
L. fermentum, L. reuteri Native Immune 
Improvement of histology in a TNBS model of rat colitis, decreased 
levels of TNF- and iNOS expression. [79] 
L. casei Shirota Native Immune 
Improvement in murine chronic inflammatory bowel disease, down-
regulation of pro-inflammatory cytokines such as IL-6 and IFN-. [80] 
L. casei DN-114 001 Native Immune 
Reduction in numbers of activated T lymphocytes in the lamina 
propria of Crohn's disease mucosa, decrease of IL-6 and TNF-. [39] 
L. rhamnosus GG Native Immune Alleviating intestinal inflammation, decrease TNF-. [46] 
VSL#3  Native Unknown 
Delayed the relapse into pouchitis after surgical resection in human 
patients. 
[27] 
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L. rhamnosus GG, L. rhamnosus 
Lc705, P. freudenreichii ssp. sher-
manii JS and B. breve Bb99.  
Native Unknown Alleviating irritable bowel syndrome symptoms. [22] 
B.and L.plantarum Native Unknown 
Improvement of the disease activity index in an induced rat colitis 
model. 
[81] 
L. rhamnosus GG Native Unknown 
Improvement in the clinical status in children with mildly to moder-
ately active stable Crohn's disease. 
[18] 
L. casei Shirota Native Unknown 
Improvement in the clinical condition of murine model of ulcerative 
colitis. 
[82] 
E. coli Nissle 1917 Native Immune 
Ameliorated colitis and decreased pro-inflammatory cytokine secre-
tion via TLR-2- and TLR-4-dependent pathways in DSS-induced 
model of IBD. 
[83] 
L. rhamnosus Lr32 or L. 
salivarius Ls33 
Native Immune 
Stimulation of DC regulatory functions by targeting specific pattern-
recognition receptors and pathways. 
[84] 
L. plantarum HY115 and L. brevis 
HY7401 
Native Immune 
Inhibition of NF-kB pathway, with decrease of pro-inflammatory 
cytokines. 
Reduction of degradation activities of chondroitin sulfate and 
hyaluronic acid of intestinal bacteria, induced by DSS. 
[85] 
Lc. lactis subsp. cremoris FC Native Unknown inhibition of inflammatory cell infiltration [86] 
B. longum HY8004 and L. planta-
rum AK8-4 
Native Immune 
Inhibition of NF-kB pathway and TLR4 expression, with decrease of 
pro-inflammatory cytokines. Reduction of intestinal bacterial gly-
cosaminoglycan (GAG) degradation. 
[87] 
VSL#3-derived L. casei Native Immune 
Induction of posttranslational degradation of T-cell chemokine inter-
feron-inducible protein (IP)-10 in intestinal epithelial cells contrib-
utes to the anti-inflammatory effects of VSL#3. 
[88] 
B. bifidum 17 Native Immune 
Inhibition of Th1-driven intestinal inflammation with reduction of 
pro-inflammatory cytokines (IL-1, IL-6), keratinocyte derived 
chemokine (KC), cyclooxygenase 2 (Cox-2) and myeloperoxidase 
(MPO) using a TNBS– induced model. 
[89] 
L. plantarum Lp91 Native Immune 
Down regulation of TNF-a and COX2 and up-regulation of IL-10 
gene expression. 
[90] 
Probiotic yoghurt Native Immune 
Diminution of the acute episode and prevention of recurrence in a 
TNBS induced mouse model. Decrease of pro-inflammatory cytoki-
nes (IFN, IL-12 and IL-17) and TLR4 expression. Increase of IL-10 
and TLR-9. Changes in the intestinal microbiota. 
[91, 
92] 
L. plantarum NCIMB8826 Dlt GM Immune 
Reduction of secretion of proinflammatory cytokines by peripheral 
blood mononuclear cells and monocytes and increase in IL-10 pro-
duction in a murine colitis model.  
[93] 
Lc. lactis IL-10 GM Immune Reduction in colitis in mice treated with DSS. [43] 
L. casei BL23 MnKat GM CAT Reduction of cecal and colonic inflammatory scores. [67] 
Lc. lactis + KatE GM CAT 
Slight increase in catalase activities in the intestines and prevention 
of colon cancer of mice administered the cancer inducing drug DMH. 
[66] 
Lc.lactis NZ9800 and L.plantarum 
NCIMB8826 + pNZ804 sodA 
GM SOD 
Reduction in macroscopic damages in rats administered with TNBS 
to induce colitis 
[72] 
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L. gasseri NC1501 GM SOD Reduction in inflammation in IL-10-deficient mice.  [73] 
L. casei BL23 MnSOD GM SOD 
Reduction of oxidative stress and intestinal inflammation scores in 
the DSS model, using Lb. casei MnSOD alone or in combination 
with Lb. casei MnKat. 
[74] 
L. casei BL23 MnKat and MnSOD GM CAT or SOD 
Faster recovery of initial weight loss, increased enzymatic activities 
in the gut, reduction of inflammatory scores and microbial trasloca-
tion to liver using a TNBS-induced model in mice. 
[71] 
Lc. lactis IL-10 GM Immune Modulation of acute allergic airway inflammation in mice. [76] 
Lc. lactis IL-10 GM Immune 
Reduction of damage scores in the large intestines, IFN- levels in 
their intestinal fluids and microbial translocation to liver using a 
TNBS-induced model in mice. 
[77] 
*microbial abbreviations: B. (Bifidobacterium). L. (Lactobacillus), St. (Streptococcus), P. (Propionibacterium), Lc. (Lactococcus). 
 
 These preliminary studies would also need to be per-
formed in larger mammals before implying to safe use in the 
design of phase I human clinical trials and the removal of 
antibiotic resistance markers in the producing strains is also 
necessary before their employment in the design of novel 
therapeutical products that could be used in human studies.  
 The consumption of engineered strains by humans is still 
highly controversial due to public perception that genetic 
manipulation is not “natural”. Scientist must perform well-
designed studies where the results are divulged to the general 
populations in order to inform consumers of the obvious 
beneficial effects these novel techniques can confer with the 
minimum of risk to their health and to the environment. 
Throughout the course of history most novel treatments have 
been met with resistance from potential benefactors, it is thus 
important to show that the potential benefits are highly supe-
rior to the risks for novel treatments to be completely ac-
cepted by the population as a whole. 
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